MX2010005520A - Peptidos con capacidad para unirse a escurfina y aplicaciones. - Google Patents

Peptidos con capacidad para unirse a escurfina y aplicaciones.

Info

Publication number
MX2010005520A
MX2010005520A MX2010005520A MX2010005520A MX2010005520A MX 2010005520 A MX2010005520 A MX 2010005520A MX 2010005520 A MX2010005520 A MX 2010005520A MX 2010005520 A MX2010005520 A MX 2010005520A MX 2010005520 A MX2010005520 A MX 2010005520A
Authority
MX
Mexico
Prior art keywords
peptides
scurfin
bind
regulating
activity
Prior art date
Application number
MX2010005520A
Other languages
English (en)
Spanish (es)
Inventor
Jesus Prieto Valtuena
Juan Jose Lasarte Sagastibelza
Francisco Borras Cuesta
Pablo Sarobe Ugarriza
Ines Noelia Casares Lagar
Original Assignee
Proyecto Biomedicina Cima Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proyecto Biomedicina Cima Sl filed Critical Proyecto Biomedicina Cima Sl
Publication of MX2010005520A publication Critical patent/MX2010005520A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2010005520A 2007-11-19 2008-11-14 Peptidos con capacidad para unirse a escurfina y aplicaciones. MX2010005520A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200703052A ES2328776B1 (es) 2007-11-19 2007-11-19 Peptidos con capacidad para unirse a escurfina y aplicaciones.
PCT/ES2008/000716 WO2009065982A1 (es) 2007-11-19 2008-11-14 Péptidos con capacidad para unirse a escurfina y aplicaciones

Publications (1)

Publication Number Publication Date
MX2010005520A true MX2010005520A (es) 2010-09-28

Family

ID=40409793

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010005520A MX2010005520A (es) 2007-11-19 2008-11-14 Peptidos con capacidad para unirse a escurfina y aplicaciones.

Country Status (11)

Country Link
US (1) US8524860B2 (https=)
EP (1) EP2223998B1 (https=)
JP (1) JP5385910B2 (https=)
CN (1) CN101903514B (https=)
AU (1) AU2008327792B2 (https=)
BR (1) BRPI0819311A2 (https=)
CA (1) CA2706201A1 (https=)
ES (1) ES2328776B1 (https=)
MX (1) MX2010005520A (https=)
RU (1) RU2502741C2 (https=)
WO (1) WO2009065982A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8080518B2 (en) * 2007-12-05 2011-12-20 Arbor Vita Corporation Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
EP3682895A1 (en) 2009-06-10 2020-07-22 NoNO Inc. Co-administration of an agent linked to a tat-internalization peptide with a mast cell degranulation inhibitor
US10196608B2 (en) * 2014-02-21 2019-02-05 Cellectis Method for in situ inhibition of regulatory T cells
ES2665543B1 (es) * 2016-10-26 2019-02-12 Fundacion Para La Investig Medica Aplicada Péptidos de unión a FOXP3 y usos de los mismos

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698015A (en) * 1995-05-19 1997-12-16 Nikko Company Conductor paste for plugging through-holes in ceramic circuit boards and a ceramic circuit board having this conductor paste
CA2314267A1 (en) * 1997-12-10 1999-06-17 Washington University Anti-pathogen system and methods of use thereof
EP1105479B1 (en) * 1998-08-11 2011-01-12 Darwin Discovery Limited Identification of the gene causing the mouse scurfy phenotype and its human ortholog
WO2001059115A2 (en) * 2000-02-09 2001-08-16 Agensys, Inc. 83p5g4: a tissue specific protein highly expressed in prostate cancer
US20030191073A1 (en) * 2001-11-07 2003-10-09 Challita-Eid Pia M. Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
US7507542B2 (en) * 2001-05-08 2009-03-24 Ucb Sa Method for regulating immune function using the FOXP3 protein
US20080085261A1 (en) * 2004-10-19 2008-04-10 Haynes Barton F Vaccine Adjuvant
US20100061984A1 (en) * 2006-01-20 2010-03-11 The Trustees Of The University Of Pennsylvania Compositions and methods for modulation of suppressor t cell activation

Also Published As

Publication number Publication date
ES2328776A1 (es) 2009-11-17
EP2223998B1 (en) 2015-05-13
CA2706201A1 (en) 2009-05-28
CN101903514A (zh) 2010-12-01
AU2008327792B2 (en) 2014-04-24
RU2502741C2 (ru) 2013-12-27
US20100267623A1 (en) 2010-10-21
US8524860B2 (en) 2013-09-03
WO2009065982A1 (es) 2009-05-28
AU2008327792A1 (en) 2009-05-28
CN101903514B (zh) 2013-07-17
RU2010125199A (ru) 2011-12-27
ES2328776B1 (es) 2010-07-06
JP5385910B2 (ja) 2014-01-08
EP2223998A1 (en) 2010-09-01
JP2011504108A (ja) 2011-02-03
BRPI0819311A2 (pt) 2015-06-16

Similar Documents

Publication Publication Date Title
SG178797A1 (en) Oligosaccharide chain added glp-1 peptide
MX341883B (es) Composicion farmaceutica para el tratamiento y prevencion de canceres.
EP2455460A3 (en) Lipase variants for pharmaceutical use
IL187321A0 (en) Host cell specific binding molecules capable of neutralizing viruses and uses thereof
NZ608502A (en) Polypeptides that bind to human complement component c5
EA201001014A1 (ru) Фармацевтически приемлемые соли метил (3-{[[3-(6-амино-2-бутокси-8-оксо-7,8-дигидро-9h-пурин-9-ил)пропил](3-морфолин-4-илпропил)амино]метил}фенил)ацетата и их применение в терапии
PH12014500923A1 (en) Insulinotropic peptide derivative wherein its n-terminal amino acid is modified
WO2007101710A8 (en) Use of inhibitors of scavenger receptor class proteins for the treatment of infectious diseases
PT2222669E (pt) Derivados de oxadiazole ativos em esfingosina-1-fosfato (s1p)
EA200802184A1 (ru) Фармацевтические композиции с ингибиторами dpp iv
IL189452A0 (en) Therapy with cd4 binding peptides and radiation
MX358224B (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer de higado.
NZ702801A (en) Treatment of sanfilippo syndrome type b
WO2007112940A3 (en) Albumin-derived amino acid sequence, use thereof for increasing the half-life of therapeutic proteins and of other therapeutic compounds and entities, and constructs comprising the same
NZ603200A (en) Peptides and their use
WO2008069917A3 (en) Novel cyclic peptides
NZ601142A (en) Composition for improving brain function and method for improving brain function
JP2011528897A5 (https=)
TW200633992A (en) Biaryloxymethylarenecarboxylic acids
MY169650A (en) Crystalline recombinant interferon with altered spatial configuration,three-dimensional structure and uses thereof
TW200800954A (en) Novel crystal modifications
MX2009009952A (es) Sal clorhidrato de 5-[3-(3-hidroxifenoxi)azetidin-1-il]-5-metil-2, 2-difenilhexanamida.
MX2010005520A (es) Peptidos con capacidad para unirse a escurfina y aplicaciones.
TW200716138A (en) Stable active compound complex of salts of O-acetylsalicylic acid with basic amino acids and glycine
MX2009010483A (es) 5-oxoisoxazoles como inhibidores de lipasas y fosfolipasas.

Legal Events

Date Code Title Description
FG Grant or registration